title: Sirolimus-eluting stent treatment as buffer for inflamed lesions identified by serum marker estimation. The STABILISE pilot study.
authors.forename: Ahmed A
authors.initials: AA
authors.lastname: Khattab
authors.forename: Caroline
authors.initials: C
authors.lastname: Röther
authors.forename: Ralph
authors.initials: R
authors.lastname: Toelg
authors.forename: Bettina
authors.initials: B
authors.lastname: Schwarz
authors.forename: Kenneth
authors.initials: K
authors.lastname: Mier
authors.forename: Volker
authors.initials: V
authors.lastname: Geist
authors.forename: Daniel
authors.initials: D
authors.lastname: Drömann
authors.forename: Torsten
authors.initials: T
authors.lastname: Schäfer
authors.forename: Gert
authors.initials: G
authors.lastname: Richardt
mesh_terms: D000368:Aged; D000787:Angina Pectoris / Q000097:blood / Q000628:therapy*; D015906:Angioplasty, Balloon, Coronary; D002499:Centrifugation, Density Gradient; D005260:Female; D005340:Fibrinogen / Q000378:metabolism; D005434:Flow Cytometry; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D007963:Leukocytes, Mononuclear / Q000378:metabolism; D018950:Lipopolysaccharide Receptors / Q000378:metabolism; D008297:Male; D008565:Membrane Proteins / Q000378:metabolism*; D010865:Pilot Projects; D011446:Prospective Studies; D020123:Sirolimus / Q000008:administration & dosage*; D015607:Stents; D013997:Time Factors; D051195:Toll-Like Receptor 2 / Q000378:metabolism; D051197:Toll-Like Receptor 4 / Q000378:metabolism
chemical_list: D007166:Immunosuppressive Agents; D018950:Lipopolysaccharide Receptors; D008565:Membrane Proteins; C495342:TLR2 protein, human; C495345:TLR4 protein, human; D051195:Toll-Like Receptor 2; D051197:Toll-Like Receptor 4; D005340:Fibrinogen; D020123:Sirolimus